Astrana Health financials
$35.45+0.91%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $3.18B | $2.03B |
| Gross profit | $341.5M | $271.4M |
| Gross margin | 10.7% | 13.3% |
| Operating income | $78.5M | $89.3M |
| Net income | $22.5M | $43.1M |
| Net margin | 0.7% | 2.1% |
| Diluted EPS | $0.46 | $0.90 |
| EBITDA | $124.3M | $117.3M |
| Operating cash flow | $114.6M | $52.2M |
| Free cash flow | $104.5M | $44.2M |
| Diluted shares | 49.4M | 48.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $429.5M | $288.5M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $1.04B | $434.7M |
| Total assets | $2.22B | $1.35B |
| Total liabilities | $1.66B | $840.7M |
| Shareholders' equity | $793.3M | $716.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology